The first IL-11 blocking drug for longevity just entered human clinical trials.
They dosed the first patient.
IL-11 is a pro-inflammatory cytokine that appears to accelerate the aging process in mice… and likely humans as well. It is an inflammatory molecule produced in excess by our immune systems as we get older. It has been linked to numerous diseases, including heart disease.
Google’s Calico Labs is backing this new drug with $600M in funding.
This is exciting.
An influencial study published last year in the prestigious journal Nature showed that blocking IL-11 produces a 22-25% median lifespan extension in both male and female mice, even when started late in life. They also showed a big extension in maximum lifespan, which is rare.
See these past posts in the group:
↪ Blocking IL-11 extended mouse lifespan ~25%; diets and drugs that may lower it listed
↪ Colchicine may work partly by inhibiting IL-11, a lifespan-linked pro-fibrotic cytokine
Also see these past posts in the rapamycin group:
Quoted:
“Calico bet $600 million on this drug last summer. Now it’s in human trials—and the race to turn a mouse longevity breakthrough into a pill you might actually take has officially begun.”
“On December 29, 2025, a patient in Shanghai received the first dose of an experimental drug that scientists hope could slow human aging.
The drug, called 9MW3811, is an antibody that blocks a protein called interleukin-11 (IL-11). In mice, blocking IL-11 extended lifespan by up to 25%—one of the largest effects ever seen from a single intervention. Now, for the first time, we’re about to find out if it works in humans.
This isn’t just another promising mouse study destined to languish in academic journals. In June 2025, Google’s longevity-focused subsidiary Calico paid $25 million upfront—with up to $571 million more in milestone payments—to license this drug for development worldwide. When Alphabet bets over half a billion dollars on an anti-aging therapy, it’s worth paying attention.”
“The Duke-NUS researchers found that IL-11 regulates a critical signaling pathway called ERK—AMPK—mTORC1. If those acronyms sound familiar, they should—AMPK activation and mTOR inhibition are precisely what longevity drugs like metformin and rapamycin target. But to be clear: 9MW3811 is not rapamycin. Unlike rapamycin, which directly inhibits mTOR, IL-11 inhibition works upstream by blocking the inflammatory signal that dysregulates these pathways. It’s an entirely different drug with a distinct mechanism—one that may avoid some of rapamycin’s immunosuppressive side effects.”
“Mabwell had already completed Phase I trials in healthy volunteers in both China and Australia. The results showed a favorable safety profile and—crucially—a half-life exceeding one month. That means a single injection could potentially provide weeks of IL-11 suppression.
The drug also has an open IND (Investigational New Drug application) with the FDA, clearing the path for U.S. trials.”
#il11HD #calicoHD #agingHD #longevityHD #mtorHD #inflammationHD #ampkHD #rapamycinHD




